Role of BARriers in IgG-Pathogen Interactions At the Mucosal Surface in Human Airways

Launched by UNIVERSITY HOSPITAL, TOURS · Oct 31, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for adults with non-cystic fibrosis bronchiectasis (NCFB), a chronic lung condition that causes a persistent cough and difficulty breathing due to damage in the airways. Researchers want to understand how inhaled immunoglobulin G (IgG), a type of antibody, interacts with mucus in the airways. The goal is to see if IgG can effectively bind to and help eliminate harmful germs, as well as how mucus affects this process. By collecting sputum samples from patients after inhaling saline, the study will look at the types of germs present and how well the IgG can work in the presence of mucus.

To participate in this study, individuals must be at least 18 years old and have a confirmed diagnosis of NCFB with specific imaging results showing bilateral bronchiectasis. They should be stable in their condition for at least four weeks. Participants will provide sputum samples for testing and may help researchers better understand how inhaled antibody treatments can be improved. The trial is not yet recruiting, but it aims to gather important information that could enhance future therapies for patients with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Clinical diagnosis of NCFB
• • Computed tomography (CT) evidence of bilateral bronchiectasis
• • Consent for research use of data and material
• • Ability to provide an induced sputum sample
• • Stable clinical status over the last 4 weeks
• Exclusion Criteria:
• • Pulmonary disease other than NCFB (except asthma)
• • Diagnosis of cystic fibrosis
• • Diagnosis of primary ciliary dyskinesia
• • Requirement for oxygen therapy at rest
• • Diagnosis of IgG deficiency (total serum IgG \< 5.4 g/l)
• • Treatment with a CFTR modulator drug in the last 6 months
• • Unilateral bronchectasis
• • CT evidence of interstitial lung disease with traction bronchectasis
• • Refusal of the patient
• • Acute exacerbation of NFCB in the last 4 weeks
• • No sputum production
• • Current treatment with systemic antibiotics (other than low dose azithromycin)
• • Pregnancy or breastfeeding
• • Subject under legal protection (e.g., guardianship, tutorship).
• • Inability to produce a sputum sample